Progressive multifocal leukoencephalopathy after CAR-T cell therapy
Michael Montoya,Hannah J. Harmsen,Brittney Baer,Nancy Long,Amy Messimore,Reena V. Jayani,Adetola Kassim,Andrew P. Jallouk,James Jerkins,Eden A. Biltibo,Bipin N. Savani,Bhagirathbhai Dholaria,Olalekan Oluwole,David S. Morgan
DOI: https://doi.org/10.1038/s41409-024-02410-3
2024-09-11
Bone Marrow Transplantation
Abstract:Progressive multifocal leukoencephalopathy (PML) is a rare and devastating viral infection that affects the central nervous system (CNS) of severely immunocompromised patients. Lymphodepletion followed by chimeric antigen receptor T cell (CAR-T) therapy to treat certain hematologic malignancies can result in prolonged immunocompromised status. The recipients of CAR-T therapy are at risk of opportunistic infections including progressive multifocal leukoencephalopathy (PML). CAR-T therapy itself is associated with early and late neurotoxicities and can make the diagnosis of PML difficult [1]. Given its high mortality rate (30–50%) in the first few months following initial diagnosis, early rapid diagnosis is important to prevent permanent neurological damage [2]. Here, we discuss a case of PML in a patient with relapsed diffuse large B cell lymphoma (DLBCL) two years after the CD19 CAR-T therapy. We have also provided a table summary of four other published cases of PML after CAR-T therapy and reviewed relevant literature on the management. A 73-year-old female with DLBCL, refractory to R-CHOP and lenalidomide and Revlimid was referred for CD19-directed CAR-T therapy. She received fludarabine and cyclophosphamide (Flu/Cy) lymphodepletion followed by axicabtagene ciloleucel (axi-cel, CD19-directed CAR-T therapy) on the ZUMA-1 clinical trial (NCT02348216). Early complications included grade 2 cytokine release syndrome (CRS) and grade 2 immune effector cell neurotoxicity syndrome (ICANS). She received tocilizumab and dexamethasone, with a resolution of these side effects. Subsequent PET/CT scan showed complete remission. She developed persistent hypogammaglobulinemia following CAR-T and was treated with intravenous immunoglobulin (IVIG). She also developed COVID-19 infection twice (6 months and 9 months) after axi-cel, for which she was treated with hydroxychloroquine and convalescent plasma.
oncology,immunology,hematology,transplantation